Literature DB >> 17004049

[A comparison of respiratory muscle strength, pulmonary function tests and endurance in patients with early and late stage ankylosing spodylitis].

G Sahin1, H Guler, M Calikoglu, M Sezgin.   

Abstract

BACKGROUND: Ankylosing spondylitis (AS) is a multisystemic disease in which pulmonary function is altered owing mainly to the restriction of chest wall involvement. A restrictive ventilatory defect has been extensively reported. This has been suggested to be a consequence of reduced mobility of the thoracic cage. Respiratory function in AS shows a typical restrictive pattern but pulmonary compliance, diffusion capacity, and arterial blood gases are normal.
OBJECTIVE: The objective of the present study was to compare pulmonary function tests (PFT), respiratory muscle strength (MIP, MEP) and endurance (MVV) in early and late AS.
METHODS: A total of 35 patients (30 males, 5 females) took part, all of whom met the New York criteria for AS. Patients were divided into two groups for the comparison of early (disease duration <10 years, 20 patients) and late (disease duration >10 years, 15 patients) manifestations in pulmonary function tests, respiratory muscle strength and endurance, dyspnea score, chest expansion, and BASFI score. In addition, 21 healthy controls were compared with the AS patients. Measurement of chest expansion was performed in all subjects. Pulmonary function tests were performed by spirometry. Respiratory muscle strength was evaluated by a mouth pressure meter (MPM). Functional status was assessed by BASFI in all AS patients.
RESULTS: There was no significant difference in body mass index between the groups. The FVC and FEV(1) were significantly lower in late AS (p=0.003, p=0.03, restrictive ventilatory defect ). Chest expansion was significantly lower in late AS (p<0.05). There was no significant difference for MIP or MEP values between late AS, early AS and the controls (p>0.05). Endurance (MVV) was significantly lower in late AS patients (p=0.05). Although the BASFI and dyspnea scores were higher in late AS, they did not reach significant levels. In addition, age was negatively correlated with MIP and MEP in late AS (r=-0.733; p=0.02, r=-0.667; p=0.05).
CONCLUSION: This study demonstrates that FVC and FEV(1) (hallmarks of a restrictive pattern), MVV (endurance) and chest expansion are especially involved in long-standing AS. Therefore, improvement of the thoracic cage should be taken into consideration, especially in early AS. These patients should be encouraged to make regular respiratory exercises for preventing the limitation of chest expansion and also improving cardiopulmonary fitness and respiratory endurance.

Entities:  

Mesh:

Year:  2006        PMID: 17004049     DOI: 10.1007/s00393-006-0080-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  18 in total

Review 1.  Measurement of lung volumes.

Authors:  A L Ries
Journal:  Clin Chest Med       Date:  1989-06       Impact factor: 2.878

Review 2.  Spirometry and flow-volume curves.

Authors:  R M Gardner; R O Crapo; S B Nelson
Journal:  Clin Chest Med       Date:  1989-06       Impact factor: 2.878

3.  Maximal respiratory pressures: normal values and relationship to age and sex.

Authors:  L F Black; R E Hyatt
Journal:  Am Rev Respir Dis       Date:  1969-05

4.  An investigation of factors limiting aerobic capacity in patients with ankylosing spondylitis.

Authors:  R Carter; P Riantawan; S W Banham; R D Sturrock
Journal:  Respir Med       Date:  1999-10       Impact factor: 3.415

5.  Exercise performance of subjects with ankylosing spondylitis and limited chest expansion.

Authors:  C G Elliott; T R Hill; T E Adams; R O Crapo; R M Nietrzeba; R M Gardner
Journal:  Bull Eur Physiopathol Respir       Date:  1985 Jul-Aug

6.  Comparison of early and late pleuropulmonary findings of ankylosing spondylitis by high-resolution computed tomography and effects on patients' daily life.

Authors:  Remzi Altin; Senay Ozdolap; Ahmet Savranlar; Selda Sarikaya; Meltem Tor; Levent Kart; Hüseyin Ozdemir
Journal:  Clin Rheumatol       Date:  2004-07-20       Impact factor: 2.980

Review 7.  The seronegative spondyloarthropathies.

Authors:  J M Kettering; J D Towers; D A Rubin
Journal:  Semin Roentgenol       Date:  1996-07       Impact factor: 0.800

8.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

9.  Lumbar stiffness but not thoracic radiographic changes relate to alteration of lung function tests in ankylosing spondylitis.

Authors:  L Cerrahoglu; Z Unlu; M Can; C Goktan; P Celik
Journal:  Clin Rheumatol       Date:  2002-08       Impact factor: 2.980

Review 10.  Pulmonary manifestations of ankylosing spondylitis and relapsing polychondritis.

Authors:  T L Lee-Chiong
Journal:  Clin Chest Med       Date:  1998-12       Impact factor: 2.878

View more
  4 in total

1.  The efficiency of inspiratory muscle training in patients with ankylosing spondylitis.

Authors:  Bilge Basakci Calik; Elif Gur Kabul; Harun Taskın; Orcin Telli Atalay; Ummuhan Bas Aslan; Murat Tascı; Fahrettin Bıcakcı; Ali Ihsan Yıldız
Journal:  Rheumatol Int       Date:  2018-06-25       Impact factor: 2.631

Review 2.  Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Authors:  Cecilia Mercieca; Irene E van der Horst-Bruinsma; Andrew A Borg
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

3.  Restrictive pulmonary function is more prevalent in patients with ankylosing spondylitis than in matched population controls and is associated with impaired spinal mobility: a comparative study.

Authors:  Gunnhild Berdal; Silje Halvorsen; Désirée van der Heijde; Morten Mowe; Hanne Dagfinrud
Journal:  Arthritis Res Ther       Date:  2012-01-25       Impact factor: 5.156

4.  Tolerability of inhaled N-chlorotaurine in humans: a double-blind randomized phase I clinical study.

Authors:  Roland Arnitz; Markus Stein; Petra Bauer; Barbara Lanthaler; Herbert Jamnig; Sabine Scholl-Bürgi; Katharina Stempfl-Al-Jazrawi; Hanno Ulmer; Bernhard Baumgartner; Sabine Embacher; Simon Geisler; Johanna M Gostner; Bernhard Müllinger; Beate Kälz; Markus Nagl
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.